Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Related Articles by Review for PubMed (Select 21836612)

1.

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.

Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, Maciejewski J, Saunthararajah Y.

Leukemia. 2012 Feb;26(2):244-54. doi: 10.1038/leu.2011.207. Epub 2011 Aug 12.

2.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Sekeres MA.

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24309530
3.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Estey EH.

Leukemia. 2013 Sep;27(9):1803-12. doi: 10.1038/leu.2013.173. Epub 2013 Jun 12. Review.

PMID:
23757301
4.

The role of decitabine for the treatment of acute myeloid leukemia.

Ganetsky A.

Ann Pharmacother. 2012 Nov;46(11):1511-7. doi: 10.1345/aph.1R151. Epub 2012 Oct 31. Review.

PMID:
23115225
5.

The role of hypomethylating agents in the treatment of elderly patients with AML.

Al-Ali HK, Jaekel N, Niederwieser D.

J Geriatr Oncol. 2014 Jan;5(1):89-105. doi: 10.1016/j.jgo.2013.08.004. Epub 2013 Sep 24. Review.

6.

[Research progress of epigenetic drug decitabine in AML].

Zhang R, Li HM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1467-71. doi: 10.7534/j.issn.1009-2137.2014.05.054. Review. Chinese.

PMID:
25338609
7.
8.

Pharmacokinetic evaluation of decitabine for the treatment of leukemia.

Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):661-72. doi: 10.1517/17425255.2011.575062. Review.

PMID:
21500965
9.

Decitabine.

Hackanson B, Daskalakis M.

Recent Results Cancer Res. 2014;201:269-97. doi: 10.1007/978-3-642-54490-3_18. Review.

PMID:
24756800
10.

Decitabine in chronic leukemias.

Issa JP, Byrd JC.

Semin Hematol. 2005 Jul;42(3 Suppl 2):S43-9. Review.

PMID:
16015505
11.

p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B.

Semin Oncol. 2012 Feb;39(1):97-108. doi: 10.1053/j.seminoncol.2011.11.011. Review.

12.

DNA methylation in haematological malignancies: the role of decitabine.

Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ.

Expert Opin Investig Drugs. 2003 Dec;12(12):1985-93. Review.

PMID:
14640942
13.

New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells.

Jeong M, Goodell MA.

Exp Hematol. 2014 Aug;42(8):609-17. doi: 10.1016/j.exphem.2014.04.008. Epub 2014 Jun 30. Review.

14.

The mechanistic role of DNA methylation in myeloid leukemogenesis.

Jasielec J, Saloura V, Godley LA.

Leukemia. 2014 Sep;28(9):1765-73. doi: 10.1038/leu.2014.163. Epub 2014 May 20. Review.

PMID:
24913729
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk